Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 9,367 matching trials from the live ClinicalTrials.gov search.

Filters: Portland, Oregon Clear all

Conditions: Cystic Fibrosis
Interventions: CTX-4430, Placebo; Drug
Lead sponsor: Celtaxsys, Inc.; Other
Eligibility: 18 Years to 30 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 39
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 34 more

Conditions: Stimulant Dependence
Interventions: Not listed
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 99 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Jacksonville, Florida • Columbus, Ohio • Eugene, Oregon + 3 more

Conditions: Pancreatic Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure; Procedure · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 50 Years to 75 Years
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2034
U.S. locations: 413
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 294 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Artificial Pancreas Control system (APC), Pacific Diabetes Technologies CGM Insulin Infusion system; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer Female
Interventions: Internet-based Intervention; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 236
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Antioch, California + 199 more

Conditions: Health Status Unknown, Prostate Carcinoma
Interventions: 3 Tesla Magnetic Resonance Imaging, Gadodiamide, Multiparametric Magnetic Resonance Imaging, Transrectal Biopsy, Ultrasound-Guided Prostate Biopsy; Procedure · Radiation
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
Interventions: tucatinib, trastuzumab, fulvestrant; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 76
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more

Conditions: Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myelomonocytic Leukemia (M4), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions: idarubicin, cytarabine, bortezomib, etoposide, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 77
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 72 more

Conditions: Major Depressive Disorder
Interventions: tasimelteon, placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 40
States / cities: Garden Grove, California • Irvine, California • Los Alamitos, California + 36 more

Conditions: Anterior Cruciate Ligament Injuries
Interventions: The BEAR® Implant; Device
Lead sponsor: Miach Orthopaedics; Industry
Eligibility: 14 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Redwood City, California • Steamboat Springs, Colorado • Orlando, Florida + 5 more

Conditions: Atopic Dermatitis
Interventions: LY3375880, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Fountain Valley, California • Los Angeles, California • Northridge, California + 11 more

Conditions: Lymphoma
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine, keyhole limpet hemocyanin, sargramostim, cyclophosphamide, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: Genitope Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 21
States / cities: Dublin, California • Greenbrae, California • Los Angeles, California + 16 more

Conditions: Menorrhagia
Interventions: Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 37
States / cities: Tucson, Arizona • Beverly Hills, California • Carmichael, California + 32 more

Conditions: Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma, Esophageal Cancer
Interventions: CX-2029; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Encinitas, California • Los Angeles, California + 12 more

Conditions: Seasonal Allergic Rhinitis
Interventions: levocetirizine dihydrochloride, placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 38
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 35 more

Conditions: Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Neoplasm of Uncertain Malignant Potential, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, T-Cell Large Granular Lymphocyte Leukemia
Interventions: Cytology Specimen Collection Procedure; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 2,545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 175
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 132 more

Conditions: Thyroid Cancer
Interventions: Lenvatinib, Lenvatinib matching placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: La Jolla, California • San Diego, California • Torrance, California + 11 more

Conditions: Breast Cancer
Interventions: Paclitaxel, BKM120 matching placebo, BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 21
States / cities: Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more

Conditions: Psoriasis
Interventions: CP-690,550, Placebo Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 14
States / cities: Irvine, California • San Diego, California • Chicago, Illinois + 9 more

Conditions: Chronic Insomnia
Interventions: Zolpidem, Internet Cognitive Behavioral Therapy for Insomnia (CBT-I), Trazodone; Drug · Behavioral
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Tucson, Arizona • Columbia, Missouri + 4 more

Conditions: Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis
Interventions: Deferasirox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 1,683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 27
States / cities: Little Rock, Arkansas • Berkeley, California • Orange, California + 23 more

Conditions: Chronic Graft-versus-host-disease
Interventions: INCA034176, Placebo, Corticosteroids; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 32 more

Conditions: Herpes Simplex
Interventions: Acyclovir, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 28 Days
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Spondyloarthropathies
Interventions: CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 32
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 28 more

Search by objective public record fields.

EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

An Eval of Neurocognitive Function, Oxidative Damage, and Their Association With Outcomes in METH and Cocaine Abusers.

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

Single Hormone Closed Loop Study With PDT Sensor

Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial

Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder

A Prospective Cohort Post Market Registry Evaluating Outcomes of Bridge-Enhanced ACL Restoration (BEAR®)

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma

Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Topical CP-690,550 For Chronic Plaque Psoriasis

CBT-I or Zolpidem/Trazodone for Insomnia

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis